EmbryoScope+ approved for sales in the USA

Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope+ in the USA, the world's third largest market measured in terms of number of IVF treatments.

EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. “We are delighted to now being able to offer also EmbryoScope+ to the clinics in the USA”, says Thomas Axelsson, CEO of Vitrolife.

May 12, 2018
Gothenburg
VITROLIFE AB (publ)
Thomas Axelsson, CEO

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 1.00 pm CET on May 12, 2018.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

_________________________________________________________________________________________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 370 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

Tags: